Loading clinical trials...
Loading clinical trials...
Phase II, Open Label, Single Arm Trial of Alectinib in Combination With Bevacizumab in Untreated and Previously Treated Patients With Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) With Positive ALK Driver Mutation
Conditions
Interventions
Alectinib
Bevacizumab
Locations
1
Mexico
Instituto Nacional de Cancerologia
Mexico City, Mexico
Start Date
April 8, 2020
Primary Completion Date
August 1, 2022
Completion Date
October 30, 2022
Last Updated
July 6, 2023
NCT04989322
NCT03912389
Lead Sponsor
Instituto Nacional de Cancerologia de Mexico
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions